Neumora Therapeutics, Inc.
NMRA
$1.84
-$0.13-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -18.81% | -23.95% | 0.80% | 31.21% | 51.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.06% | -31.24% | -15.33% | 18.08% | 25.59% |
| Operating Income | 7.06% | 31.24% | 15.33% | -18.08% | -25.59% |
| Income Before Tax | -1.07% | 21.71% | 10.02% | -26.37% | 45.77% |
| Income Tax Expenses | -- | -- | -80.00% | -- | -100.00% |
| Earnings from Continuing Operations | -1.07% | 21.77% | 10.17% | -26.57% | 45.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.07% | 21.77% | 10.17% | -26.57% | 45.90% |
| EBIT | 7.06% | 31.24% | 15.33% | -18.08% | -25.59% |
| EBITDA | 6.84% | 31.13% | 15.14% | -18.13% | -25.70% |
| EPS Basic | 3.45% | 22.86% | 11.67% | -23.82% | 48.64% |
| Normalized Basic EPS | 3.46% | 29.59% | 11.55% | -23.61% | -25.36% |
| EPS Diluted | 3.45% | 22.86% | 11.67% | -23.82% | 48.64% |
| Normalized Diluted EPS | 3.46% | 29.59% | 11.55% | -23.61% | -25.36% |
| Average Basic Shares Outstanding | 4.68% | 1.42% | 1.70% | 2.22% | 5.33% |
| Average Diluted Shares Outstanding | 4.68% | 1.42% | 1.70% | 2.22% | 5.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |